ArticleJournal of immunology (Baltimore, Md. : 1950)2010
Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 63 citations in OpenAlex.
- Galectins and Liver Diseases.International journal of molecular sciences · 2025Review
- Analysis of Galectin-Binding Receptors on B Cells.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Examination of Whole-Cell Galectin Binding by Solid Phase and Flow Cytometric Analysis.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Site-Specific Cross-Linking of Galectin-1 Homodimers via Poly(ethylene glycol) Bismaleimide.Cellular and molecular bioengineering · 2021Article
- Article
- Glycan characterization of pregnancy-specific glycoprotein 1 and its identification as a novel Galectin-1 ligand.Glycobiology · 2020Article
- Galectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response.Bosnian journal of basic medical sciences · 2020Article
- A Pro-resolving Role for Galectin-1 in Acute Inflammation.Frontiers in pharmacology · 2020Article
- How altering the modular architecture affects aspects of lectin activity: case study on human galectin-1.Glycobiology · 2019Article
- A chimeric, multivalent assembly of galectin-1 and galectin-3 with enhanced extracellular activity.Biomaterials science · 2019Article
- Design-functionality relationships for adhesion/growth-regulatory galectins.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- A Synthetic Tetramer of Galectin-1 and Galectin-3 Amplifies Pro-apoptotic Signaling by Integrating the Activity of Both Galectins.Frontiers in chemistry · 2019Article
- Clinicopathological significance of galectin-1 expression and percentage of galectin-1-expressing T cells in clear-cell renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018Article
- Galectin-1 Influences Breast Cancer Cell Adhesion to E-selectinCellular and molecular bioengineering · 2018Article
- Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis.Journal of molecular medicine (Berlin, Germany) · 2017Article
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Laboratory investigation; a journal of technical methods and pathology · 2017Review
- The human cytomegalovirus glycoprotein pUL11 acts via CD45 to induce T cell IL-10 secretion.PLoS pathogens · 2017Article
- Immune resolution mechanisms in inflammatory arthritis.Nature reviews. Rheumatology · 2017Review
- Regulation of Eosinophil Recruitment and Activation by Galectins in Allergic Asthma.Frontiers in medicine · 2017Review
- Engineering galectin-glycan interactions for immunotherapy and immunomodulation.Experimental biology and medicine (Maywood, N.J.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Galectin-1 (Gal-1), a β-galactoside-binding lectin, plays a profound role in modulating adaptive immune responses by altering the phenotype and fate of T cells. Experimental data showing recombinant Gal-1 (rGal-1) efficacy on T cell viability and cytokine production, nevertheless, is controversial due to the necessity of using stabilizing chemicals to help retain Gal-1 structure and function. To address this drawback, we developed a mouse Gal-1 human Ig chimera (Gal-1hFc) that did not need chemical stabilization for Gal-1 ligand recognition, apoptosis induction, and cytokine modulation in a variety of leukocyte models. At high concentrations, Gal-1hFc induced apoptosis in Gal-1 ligand(+) Th1 and Th17 cells, leukemic cells, and granulocytes from synovial fluids of patients with rheumatoid arthritis. Importantly, at low, more physiologic concentrations, Gal-1hFc retained its homodimeric form without losing functionality. Not only did Gal-1hFc-binding trigger IL-10 and Th2 cytokine expression in activated T cells, but members of the CD28 family and several other immunomodulatory molecules were upregulated. In a mouse model of contact hypersensitivity, we found that a non-Fc receptor-binding isoform of Gal-1hFc, Gal-1hFc2, alleviated T cell-dependent inflammation by increasing IL-4(+), IL-10(+), TGF-β(+), and CD25(high)/FoxP3(+) T cells, and by decreasing IFN-γ(+) and IL-17(+) T cells. Moreover, in human skin-resident T cell cultures, Gal-1hFc diminished IL-17(+) T cells and increased IL-4(+) and IL-10(+) T cells. Gal-1hFc will not only be a useful new tool for investigating the role of Gal-1 ligands in leukocyte death and cytokine stimulation, but for studying how Gal-1-Gal-1 ligand binding shapes the intensity of immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.